South Korea · Delayed Price · Currency is KRW HLB Genex Statistics
Total Valuation
HLB Genex has a market cap or net worth of KRW 61.57 billion. The enterprise value is 82.17 billion.
| Market Cap | 61.57B |
| Enterprise Value | 82.17B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HLB Genex has 32.64 million shares outstanding. The number of shares has increased by 62.65% in one year.
| Current Share Class | 32.64M |
| Shares Outstanding | 32.64M |
| Shares Change (YoY) | +62.65% |
| Shares Change (QoQ) | +8.99% |
| Owned by Insiders (%) | 12.56% |
| Owned by Institutions (%) | 2.00% |
| Float | 21.63M |
Valuation Ratios
The trailing PE ratio is 6.07.
| PE Ratio | 6.07 |
| Forward PE | n/a |
| PS Ratio | 1.35 |
| PB Ratio | 0.90 |
| P/TBV Ratio | 1.60 |
| P/FCF Ratio | 17.38 |
| P/OCF Ratio | 12.51 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.01, with an EV/FCF ratio of 23.19.
| EV / Earnings | 8.87 |
| EV / Sales | 1.80 |
| EV / EBITDA | 18.01 |
| EV / EBIT | n/a |
| EV / FCF | 23.19 |
Financial Position
The company has a current ratio of 1.08, with a Debt / Equity ratio of 0.61.
| Current Ratio | 1.08 |
| Quick Ratio | 0.90 |
| Debt / Equity | 0.61 |
| Debt / EBITDA | 7.75 |
| Debt / FCF | 11.79 |
| Interest Coverage | 0.09 |
Financial Efficiency
Return on equity (ROE) is 16.75% and return on invested capital (ROIC) is 1.37%.
| Return on Equity (ROE) | 16.75% |
| Return on Assets (ROA) | 0.48% |
| Return on Invested Capital (ROIC) | 1.37% |
| Return on Capital Employed (ROCE) | 1.18% |
| Weighted Average Cost of Capital (WACC) | 13.00% |
| Revenue Per Employee | 608.93M |
| Profits Per Employee | 123.51M |
| Employee Count | 75 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 4.01 |
Taxes
In the past 12 months, HLB Genex has paid 844.85 million in taxes.
| Income Tax | 844.85M |
| Effective Tax Rate | 7.99% |
Stock Price Statistics
The stock price has decreased by -38.77% in the last 52 weeks. The beta is 0.02, so HLB Genex's price volatility has been lower than the market average.
| Beta (5Y) | 0.02 |
| 52-Week Price Change | -38.77% |
| 50-Day Moving Average | 1,845.26 |
| 200-Day Moving Average | 2,500.19 |
| Relative Strength Index (RSI) | 54.57 |
| Average Volume (20 Days) | 204,433 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HLB Genex had revenue of KRW 45.67 billion and earned 9.26 billion in profits. Earnings per share was 310.96.
| Revenue | 45.67B |
| Gross Profit | 16.33B |
| Operating Income | 1.05B |
| Pretax Income | 10.57B |
| Net Income | 9.26B |
| EBITDA | 5.39B |
| EBIT | 1.05B |
| Earnings Per Share (EPS) | 310.96 |
Balance Sheet
The company has 35.77 billion in cash and 41.79 billion in debt, with a net cash position of -6.01 billion or -184.21 per share.
| Cash & Cash Equivalents | 35.77B |
| Total Debt | 41.79B |
| Net Cash | -6.01B |
| Net Cash Per Share | -184.21 |
| Equity (Book Value) | 68.59B |
| Book Value Per Share | 1,699.39 |
| Working Capital | 4.07B |
Cash Flow
In the last 12 months, operating cash flow was 4.92 billion and capital expenditures -1.38 billion, giving a free cash flow of 3.54 billion.
| Operating Cash Flow | 4.92B |
| Capital Expenditures | -1.38B |
| Depreciation & Amortization | 4.34B |
| Net Borrowing | -4.53B |
| Free Cash Flow | 3.54B |
| FCF Per Share | 108.52 |
Margins
Gross margin is 35.76%, with operating and profit margins of 2.29% and 20.28%.
| Gross Margin | 35.76% |
| Operating Margin | 2.29% |
| Pretax Margin | 23.14% |
| Profit Margin | 20.28% |
| EBITDA Margin | 11.81% |
| EBIT Margin | 2.29% |
| FCF Margin | 7.76% |
Dividends & Yields
HLB Genex does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -62.65% |
| Shareholder Yield | -62.65% |
| Earnings Yield | 15.05% |
| FCF Yield | 5.75% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 19, 2018. It was a forward split with a ratio of 2.
| Last Split Date | Mar 19, 2018 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
HLB Genex has an Altman Z-Score of 1.2 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.2 |
| Piotroski F-Score | 5 |